GCTK Glucotrack, Inc.
Price Chart
Executive Summary
Glucotrack announced submission of an IDE application to the FDA to initiate a US clinical study for its fully implantable continuous blood glucose monitor. This is a significant regulatory milestone for the micro-cap company, moving its CBGM technology closer to clinical evaluation, but does not guarantee approval or commercial launch.
Actionable Insight
Monitor FDA response to the IDE application; stock may be volatile on updates. Look for subsequent clinical trial enrollment announcements as the next catalyst.
Key Facts
- Glucotrack submitted an IDE application to the FDA for its fully implantable CBGM.
- The IDE submission allows the company to pursue a US clinical study pending FDA approval.
- The CBGM is designed for 3-year sensor longevity with no on-body wearable and minimal calibration.
- The company has a market cap of approximately $2M and is pre-revenue.
Financial Impact
Not quantifiable from filing; no financial terms disclosed.
Risk Factors
- FDA may not approve the IDE, delaying or halting clinical trials.
- The company may need to raise additional capital to fund clinical studies.
- Competition from established CGM players like Dexcom and Abbott.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3290388 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 15, 2026
25d ago
|
8-K
| $0.4830 $0.5950 | ▼ −23.19% | ▼ −21.57% | $0.5024 (−4.02%) |
|
May 14, 2026
26d ago
|
8-K
| $0.6500 $0.5000 | ▼ −23.08% | ▼ −24.04% | $0.5024 (−22.71%) |
|
May 7, 2026
4w ago
|
Press Release
| $0.8600 $0.7000 | ▼ −18.60% | ▼ −20.11% | $0.5024 (−41.58%) |
|
Apr 30, 2026
5w ago
|
8-K
| $0.8000 $0.8600 | ▼ −7.50% | ▼ −5.15% | $0.5024 (+37.20%) |
|
Apr 14, 2026
8w ago
|
8-K
| $0.7350 $0.7490 | ▼ −1.90% | ▼ −0.51% | $0.5024 (+31.65%) |
|
Mar 30, 2026
10w ago
|
8-K
| $0.6500 $0.6830 | ▲ +5.08% | ▲ +1.13% | $0.5024 (−22.71%) |
|
Mar 30, 2026
10w ago
|
Press Release
| $0.6500 $0.6830 | ▲ +5.08% | ▲ +1.13% | $0.5024 (−22.71%) |
|
Mar 27, 2026
10w ago
|
Press Release
| $0.9900 $0.8300 | ▼ −16.16% | ▼ −20.02% | $0.5024 (−49.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access